World's Best Scientists 2026 revealed!
Christine Katlama

Christine Katlama

Award Badge
Microbiology
France
2026

D-Index & Metrics

Microbiology

D-Index
118
Citations
57846
World Ranking
163
National Ranking
8

Medicine

D-Index
118
Citations
58848
World Ranking
4023
National Ranking
116

Christine Katlama publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Christine Katlama sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 684 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Christine Katlama D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Christine Katlama sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 118 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Microbiology in France Leader Award
  • 2025 - Research.com Microbiology in France Leader Award

Overview

Christine Katlama is affiliated with Université Paris Cité in France and specializes in medicine, with a strong focus on infectious diseases. Their research contributions encompass various subfields including infectious diseases, virology, epidemiology, emergency medicine, and hepatology.

The main topics addressed in their work include HIV/AIDS drug development and treatment, HIV research and treatment, HIV/AIDS research and interventions, HIV-related health complications and treatments, hepatitis C virus research, hepatitis B virus studies, and the long-term effects of COVID-19.

Katlama has contributed extensively to scientific literature, with notable recent papers such as:

  • 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0, 2020, HIV Medicine
  • The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes, 2020, Clinical Infectious Diseases
  • Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study, 2022, The Lancet HIV
  • Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2×2 factorial design, 2024, The Lancet Infectious Diseases
  • Evolocumab in HIV-Infected Patients With Dyslipidemia, 2020, Journal of the American College of Cardiology

Frequent collaborators in their research include:

  • Romain Palich
  • Lambert Assoumou
  • Anne-Geneviève Marcelin
  • Christoph Stephan
  • Dominique Costagliola

Katlama's research has been published predominantly in the following journals and venues:

  • Journal of Antimicrobial Chemotherapy
  • Clinical Infectious Diseases
  • Infectious Diseases Now
  • AIDS
  • UNC Libraries

Best Publications

  • Positive Effects of Combined Antiretroviral Therapy on CD4+ T Cell Homeostasis and Function in Advanced HIV Disease

    B. Autran;G. Carcelain;T. S. Li;C. Blanc

  • Isolation of a new human retrovirus from West African patients with AIDS.

    F Clavel;D Guétard;F Brun-Vézinet;S Chamaret

  • Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

    Francesca J. Torriani;Maribel Rodriguez-Torres;Jürgen K. Rockstroh;Eduardo Lissen

  • Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

    Y Benhamou;M Bochet;V Di Martino;F Charlotte

  • Decline in the AIDS and death rates in the EuroSIDA study: an observational study

    A Mocroft;B Ledergerber;C Katlama;O Kirk

  • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

    F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

    Adriano Lazzarin;Bonaventura Clotet;David Cooper;Jacques Reynes

  • Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

    TS Li;R Tubiana;C Katlama;V Calvez

  • Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort

    Deborah Konopnicki;Amanda Mocroft;S. De Wit;Francisco Antunes

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

    Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson

  • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

    Beatriz Grinsztejn;Bach Yen Nguyen;Christine Katlama;Jose M. Gatell

  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

    Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  • AIDS across Europe, 1994–98: the EuroSIDA study

    A Mocroft;C Katlama;AM Johnson;C Pradier

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.

    Yves Benhamou;Vincent Di Martino;Marie Bochet;Geneviève Colombet

  • Towards an HIV cure: a global scientific strategy

    Steven G Deeks;Brigitte Autran;Ben Berkhout;Monsef Benkirane

  • Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.

    Yves Benhamou;Marie Bochet;Vincent Thibault;Vincent Di Martino

  • Perturbation of CD4 + and CD8 + T-cell repertoires during progression to AIDS and regulation of the CD4 + repertoire during antiviral therapy

    Guy Gorochov;Avidan U. Neumann;Avidan U. Neumann;Anne Kereveur;Christophe Parizot

  • HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population.

    Charlotte Lewden;Geneviève Chene;Philippe Morlat;Francois Raffi

Frequent Co-Authors

Vincent Calvez
Vincent Calvez Centre national de la recherche scientifique, CNRS
Gilles Peytavin
Gilles Peytavin Claude Bernard University Lyon 1
Brigitte Autran
Brigitte Autran Sorbonne University
Anne-Geneviève Marcelin
Anne-Geneviève Marcelin Sorbonne University
Isabelle Poizot-Martin
Isabelle Poizot-Martin Aix-Marseille University
Guislaine Carcelain
Guislaine Carcelain Université Paris Cité
Jens D. Lundgren
Jens D. Lundgren Rigshospitalet
Geneviève Chêne
Geneviève Chêne University of Bordeaux
Nathan Clumeck
Nathan Clumeck Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in expanding their studies beyond Microbiology, pursuing related online degrees can open diverse career opportunities. For example, public health fields offer flexible options such as online mph programs easy to get into, allowing students to enter the public health sector with less competitive admissions.

Graduates may also explore specialized healthcare roles. Becoming a certified child life specialist salary is an attractive pathway for those passionate about supporting children through medical experiences while leveraging a science background.

For individuals with unique challenges, such as criminal records, education remains accessible. Resources highlighting what is the best degree for a convicted felon can guide students toward degree programs designed to support career reintegration.

Healthcare continues to evolve with fields like functional medicine gaining prominence. Aspiring nurses can pursue paths like the functional medicine nurse practitioner, blending conventional and holistic approaches to patient care.

Overall, exploring these related degrees and career choices ensures that microbiology students have versatile options tailored to diverse interests and life circumstances.

Best Scientists Citing Christine Katlama

Trending Scientists

Recently Published Articles